Latest California Healthline Stories
As health care issues hit center stage in Washington again, Kaiser Health News reporters hold forth on a number of radio and television shows.
GOP Health Plan Aims To Curb Medicaid, Expand State Options
House Republicans’ latest plan to repeal Obamacare would give states flexibility in managing their Medicaid programs, but also some difficult decisions to make.
How Millennials Win And Lose Under The GOP Health Bill
The cost of insurance could go down for people ages 26 to 29 under the GOP plan. But will they buy it without a mandate?
In Deep-Blue State, Millions in Reddish Heartland Are Counting On Medicaid
The prospect of cutbacks has led to agitation and activism in California’s largely agricultural Central Valley, with relatively high poverty rates and a significant number of Trump voters.
A Fact Check Finds Many Misleading Letters From Lawmakers On Health Care
Four news organizations read through letters sent by 51 senators and 134 members of the House dealing with the health care debate.
California Estimates It Ultimately Would Lose $24B Annually Under GOP Health Plan
“It’s challenging to see how it would not … jeopardize the entire [Medicaid] program,” a top health official said.
Low-Income AIDS Patients Fear Coverage Gains May Slip Away
The federal health law made it feasible for the AIDS Drug Assistance Program to expand its efforts and help patients buy marketplace insurance plans to cover drugs and other health care.
Trump’s Promise To Rein In Drug Prices Could Open Floodgate To Importation Laws
Sen. Bernie Sanders’ bill to allow Americans to buy cheaper medicines from Canada would bypass a requirement that blocked past legislative efforts over two decades.
California’s Republican Congress Members Face Quandary Over Health Bill
Many constituents could lose coverage under the AHCA. Half of California’s Republican-led districts voted against Donald Trump.
GAO To Launch Investigation Of FDA’s Orphan Drug Program
The Government Accountability Office said it will investigate potential abuses of the orphan drug program, which offers incentives to drugmakers to develop medicines for rare diseases.